熱門

X

    Backchat

    簡介

    GIST

    主持人:Azam Khan and CM Chan


    Backchat is RTHK Radio 3's week-daily current affairs discussion programme, with expert panels and listener participation. It airs every Monday to Friday from 9.05am - 10am (HKT).
    Have your say by calling us on 233 88 266, find us on Facebook - Backchat on RTHK Radio 3, or email backchat@rthk.gov.hk

    Listen live on Radio 3's homepage - www.rthk.hk/radio/radio3

    最新

    LATEST
    17/04/2026

    Basketball betting on hold / CUHK head and neck cancer study / Improved Heat Stress at Work Warning system / Meta CEO Mark Zuckerberg's AI clone

    On this programme, we "bounce" into action with a closer look at the government's recent move to suspend the launch of basketball betting, citing the emergence of prediction markets as a potential gateway to illegal gambling.

    After that, we hear from a study by the Chinese University of Hong Kong's faculty of medicine that found significant regional, age, and gender disparities in head and neck cancer incidence.

    After the break, we talk to a lawmaker on the Labour Department's decision to include monitoring stations in nine more locations to better decide whether to issue a Heat Stress at Work Warning.

    And to wrap up the programme, our AI consultant tells us how Meta is building an AI clone of its CEO Mark Zuckerberg to engage with employees in his stead.

    9:05am-9:20am: Basketball betting on hold

    Speaker: 

    Johnny Ng, Lawmaker

    9:20am-9:30am: CUHK head and neck cancer study

    Speaker:

    Dr. Jason Huang, study author and Assistant Professor from The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong

    9:32am-9-45am: Improved Heat Stress at Work Warning system

    Speaker:

    Lam Chun-sing, Lawmaker

    9:45am-10:00am: Meta CEO Mark Zuckerberg's AI clone

    Speaker:

    Raj Shroff, AI consultant

    17/04/2026 - 足本 Full (HKT 09:05 - 10:00)

    17/04/2026 - Basketball betting on hold

    17/04/2026 - CUHK head and neck cancer study

    17/04/2026 - Improved Heat Stress at Work Warning system

    17/04/2026 - Meta CEO Mark Zuckerberg's AI clone

    重溫

    CATCHUP
    04
    2026
    香港電台第三台
    X

    2025 IMD World Competitiveness Ranking / HKTDC Export confidence index / Dual immunotherapy treatment for liver cancer

    主持人:Azam Khan and CM Chan

    On Thursday’s Backchat, we spoke to experts about Hong Kong's significant improvement in its competitiveness. 
    The city has been named the third-most globally competitive economy in the world, climbing two places from last year, according to the 2025 IMD World Competitiveness Ranking. 
    Chief Executive John Lee hailed the report, saying it highlights Hong Kong's world-class business environment and reflects the positive views of business leaders.
    After the break, we talked to a representative from the Trade Development Council to learn more about its latest Export Confidence Index and 2025 export forecast.
    And finally, we heard from an expert about a dual immunotherapy treatment for liver cancer that has received approval from three major health authorities for global use.
    9:05am-9:30am: 2025 IMD World Competitiveness Ranking
    9:05am-9:30am: Cecilia Lam, Acting Government Economist
    9:05am-9:23am: Ho Lok Sang, Adjunct Professor at the Pan Sutong Shanghai-Hong Kong Economic Policy Research Institute, Lingnan University
    9:12am-9:30am: Robert Lee, Financial Services Sector Lawmaker 
    9:32am-9:48am: HKTDC Export confidence index
    9:32am-9:48am: Irina Fan, Director of Research at the Hong Kong Trade Development Council (HKTDC)
    9:48am-10:00am:  Dual immunotherapy treatment for liver cancer
    9:48am-10:00am: Thomas Yau Chung-cheung, Clinical Associate Professor at Li Ka Shing Faculty of Medicine, The University of Hong Kong

    香港電台第三台

    19/06/2025 - 足本 Full (HKT 09:05 - 10:00)

    19/06/2025 - 2025 IMD World Competitiveness Ranking

    19/06/2025 - HKTDC Export confidence index

    19/06/2025 - Dual immunotherapy treatment for liver cancer